Monday 8 December, 2008

Desloratadine tablets (5 mg): Perrigo settled with innovator

Perrigo pharma has announced (in a press release Here) that patent litigation w.r.t Desloratadine tablets (5 mg) has been settled with innovator Schering. Perrigo has got license from innovator for this product. Earlier, innovator Schering sued Perrigo for patent infringement of US6100274 (which covers Stable formulation), US7214683 (which covers formulation of descarboethoxyloratadine) and US7214684 (method of use of descarboethoxyloratadine) based upon its filing of an ANDA containing a Paragraph IV certification. Under the terms of the settlement, Perrigo can commercially launch its generic Desloratadine product on July 1, 2012, or earlier in certain circumstances. The new product launch may be a prescription or over-the-counter (OTC) product depending on its status at the time of launch. The Perrigo product is awaiting USFDA approval.
Earlier, innovator had sued various generic players like Zydus, Sandoz, Mylan, Orchid, Perrigo, Glenmark, GeoPharma, Lupin, Ranbaxy, Sun, Watson, Dr. Reddy's who filed ANDA to market this product.
Earlier news of Ippharmadoc on this product Here

No comments:

web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker